WHWK Whitehawk Therapeutics Inc
USHealthcareAs of 2026-10-08
Why WHWK matters now
Whitehawk Therapeutics Inc (WHWK) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.47 with +1.76% on the session and $197.8M in market capitalization; recent performance reads 1-month +8.60% and YTD +82.64%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-22.2M, and EPS of $-0.32. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -44.8%.
The latest indexable market news headline is "Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages" from Defense World.
Additional event context on this page matters because analyst consensus is Hold with a median target of $7.00; recent insider activity includes Aghazadeh Behzad filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.63
P/S
0.00
EV/EBITDA
-1.59
DCF Value
$-4.39
FCF Yield
-44.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-79.6%
ROA
-91.0%
ROIC
-105.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-22.2M | $-0.32 |
| Q4 2025 | $0.00 | $-23.3M | $-0.34 |
| FY 2025 | $7.1M | $-20.6M | $-0.33 |
| Q3 2025 | $0.00 | $-17.7M | $-0.26 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$7.00
Target (Median)
$7.00
Target Range
$7.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.77
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.